Discover trends, market shifts, and competitive outlooks for the perjeta (pertuzumab) global market report 2025 industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

How Has The Perjeta (Pertuzumab) Market Size Shifted, And What Is the Outlook Through 2034?

In recent times, there has been a significant growth in the market size of Perjeta, also known as Pertuzumab. The market, which was estimated to be worth $935.92 million in 2024, is projected to expand to $1,084.80 million in 2025, representing a compound annual growth rate (CAGR) of 15.9%. Various factors have contributed to this growth during the historical period. These include an increased application in oncology, a rising demand for ADCs, the preference for targeted and less harmful treatments, an escalation in inorganic growth, and the need for personalized and targeted medicine.

Expectations are high for the pertuzumab (perjeta) market to experience swift expansion in the upcoming years. The anticipated market size is projected to reach $1,932.66 million in 2029 with a compound annual growth rate (CAGR) of 15.5%. This surge during the forecast period can be credited to factors such as the growing instances of breast cancer, enhanced focus on ADCs for blood cancer related disorders, increasing occurrence of cancer, unfulfilled healthcare needs, and amplified R&D efforts in cancer immunotherapy within the pharmaceutical sector. Key trends to look out for within the forecast period include the integration of biosimilars within oncology treatments, the creation of biosimilars and generics medications, innovations in drug compositions, progress in research on cancer immunotherapy, and the growing significance of combination therapies.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19917&type=smp

What are the Fundamental Drivers and Innovations Shaping the Perjeta (Pertuzumab) Market?

The increase in breast cancer cases is anticipated to boost the Perjeta (pertuzumab) market’s expansion. Breast cancer is characterized by the growth of cancerous cells in the breast tissue, commonly starting in the ducts or lobules. The elevated prevalence of breast cancer can be connected to changes in lifestyle such as augmented obesity and inactive routines, as well as a better early detection rate with extensive screening programs. Perjeta (pertuzumab) serves to treat HER2-positive breast cancer by specifically aiming at the HER2 receptor, and is often used in combination with trastuzumab and chemotherapy to enhance the effectiveness of treatments. For example, the Ray of Light Wales, a charity based in the UK, reported in October 2023 that the estimated count of individuals living in the UK post their breast cancer diagnosis was around 600,000, with projections expecting this number to surge to 1.2 million by 2030. As such, the escalating occurrence of breast cancer is fuelling the growth of the herceptin biosimilars market.

How Is the Perjeta (Pertuzumab) Market Segmented?

The perjeta (pertuzumab)market covered in this report is segmented –

1) By Type: Human source; Animal source

2) By Product: Monoclonal Antibody; Biologic Drug

3) By Indication: Early Breast Cancer; Metastatic Breast Cancer

4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=19917&type=smp

Which Regions Are Driving the Next Phase of the Perjeta (Pertuzumab) Market Growth?

North America was the largest region in the perjeta (pertuzumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the perjeta (pertuzumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Key Trends Are Shaping the Future of the Perjeta (Pertuzumab) Market?

The primary trend in the Perjeta (pertuzumab) market is the emphasis on developing state-of-the-art technological solutions – specifically, subcutaneous combination treatments – to enhance patient recovery and facilitate treatment. Subcutaneous combination treatments are therapies where two or more medications are combined into a single subcutaneous injection (injected beneath the skin) to manage a specific condition. For example, Chugai Pharmaceutical Co., Ltd., a pharmaceutical company based in Japan, in November 2023, unveiled Phesgo – a subcutaneous combination therapy for HER2-positive breast cancer, as well as advanced or recurrent HER2-positive colorectal cancer. This cutting-edge treatment, which is administered subcutaneously, merges the monoclonal antibodies pertuzumab and trastuzumab with vorhyaluronidase alfa. This allows the therapy to be administered within merely 5 to 8 minutes, thus dramatically slashing the time compared to the conventional intravenous infusions. Phesgo is designed for patients with advanced or recurrent HER2-positive colorectal cancer and it’s the first of its kind to offer a subcutaneous option for this condition.

View the full report here:

https://www.thebusinessresearchcompany.com/report/perjeta-pertuzumab-global-market-report

How Is the Perjeta (Pertuzumab) Market Defined and What Are Its Core Parameters?

Perjeta (pertuzumab) is a targeted therapy used in the treatment of certain types of breast cancer. It is a monoclonal antibody that specifically binds to the human epidermal growth factor receptor 2 (HER2), a protein that promotes the growth of cancer cells in HER2-positive breast cancer.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19917

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model